内科理论与实践

内科理论与实践 >

2021 , Vol. 16 >Issue 06: 427 - 430

DOI: https://doi.org/10.16138/j.1673-6087.2021.06.012

综述

糖化血红蛋白变异性与糖尿病微血管并发症关系的研究进展

展开
  • a.内分泌代谢病科 上海交通大学医学院附属瑞金医院 上海市内分泌代谢病临床医学中心上海市内分泌代谢病研究所,上海 200025
    b.高血压科 上海市高血压研究所,上海 200025

收稿日期: 2021-08-27

  网络出版日期: 2022-07-25

基金资助

转化医学国家重大科技基础设施（上海）项目(TMSK-2021-506)

收起

本文引用格式

缪雅, 杨玉琳, 朱怡洁, 盛长生, 田景琰 . 糖化血红蛋白变异性与糖尿病微血管并发症关系的研究进展[J]. 内科理论与实践, 2021 , 16(06) : 427 -430 . DOI: 10.16138/j.1673-6087.2021.06.012

参考文献

[1] Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association[J]. BMJ, 2020, 369: m997.
[2] Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045[J]. Diabetes Res Clin Pract, 2019, 157: 107843.
[3] Li S, Nemeth I, Donnelly L, et al. Visit-to-visit HbA1c variability is associated with cardiovascular disease and microvascular complications in patients with newly diagnosed type 2 diabetes[J]. Diabetes Care, 2020, 43(2): 426-432.
[4] Virk SA, Donaghue KC, Cho YH, et al. Association between HbA1c variability and risk of microvascular com-plications in adolescents with type 1 diabetes[J]. J Clin Endocrinol Metab, 2016, 101(9): 3257-3263.
[5] Iuchi H, Sakamoto M, Matsutani D, et al. The durability of basal insulin affects day-to-day glycemic variability assessed by continuous glucose monitoring in type 2 diabetes patients[J]. Diabetes Technol Ther, 2017, 19(8): 457-462.
[6] Sun B, He F, Gao Y, et al. Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes[J]. Endocrine, 2019, 64(3): 536-543.
[7] Gorst C, Kwok CS, Aslam S, et al. Long-term glycemic variability and risk of adverse outcomes[J]. Diabetes Care, 2015, 38(12): 2354-2369.
[8] Walker GS, Chen JY, Hopkinson H, et al. Structured education using dose adjustment for normal eating (DAFNE) reduces long-term HbA1c and HbA1c variability[J]. Diabet Med, 2018, 35(6): 745-749.
[9] Wadén J, Forsblom C, Thorn LM, et al. A1c variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes[J]. Diabetes, 2009, 58(11): 2649-2655.
[10] Shen Y, Dai D, Lu J, et al. Visit-to-visit variability of glycated albumin was associated with incidence or progression of lower extremity atherosclerotic disease[J]. Cardiovasc Diabetol, 2020, 19(1): 211.
[11] Wan EY, Fung CS, Fong DY, et al. Association of variability in hemoglobin A1c with cardiovascular diseases and mortality in Chinese patients with type 2 diabetes mellitus[J]. J Diabetes Complications, 2016, 30(7): 1240-1247.
[12] Zorena K. Anti-inflammatory therapy in diabetic retinopathy[J]. Mediators Inflamm, 2014, 2014: 947896.
[13] Kollias AN, Ulbig MW. Diabetic retinopathy: early diagnosis and effective treatment[J]. Dtsch Arztebl Int, 2010, 107(5): 75-83.
[14] Hermann JM, Hammes HP, Rami-Merhar B, et al. HbA1c variability as an independent risk factor for diabetic retinopathy in type 1 diabetes: a German/Austrian multicenter analysis on 35,891 patients[J]. PLoS One, 2014, 9(3): e91137.
[15] Rosa LCGFD, Zajdenverg L, Souto DL, et al. HbA1cvariability and long-term glycemic control are linked to diabetic retinopathy and glomerular filtration rate in patients with type 1 diabetes and multiethnic background[J]. J Diabetes Complications, 2019, 33(9): 610-615.
[16] Penno G, Solini A, Bonora E, et al. HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes[J]. Diabetes Care, 2013, 36(8): 2301-2310.
[17] Foo V, Quah J, Cheung G, et al. HbA1c, systolic blood pressure variability and diabetic retinopathy in Asian type 2 diabetics[J]. J Diabetes, 2017, 9(2): 200-207.
[18] Takao T, Suka M, Yanagisawa H, et al. Predictive ability of visit-to-visit variability in HbA1c and systolic blood pressure for the development of microalbuminuria and retinopathy in people with type 2 diabetes[J]. Diabetes Res Clin Pract, 2017, 128: 15-23.
[19] 胡佳琪, 徐慧君, 刘超, 等. HbA1c变异性的影响因素及其对2型糖尿病视网膜病变的作用[J]. 中华内分泌代谢杂志, 2020, 36(5): 381-386.
[20] Ioannou K. Diabetic nephropathy: is it always there? Assumptions, weaknesses and pitfalls in the diagnosis[J]. Hormones (Athens), 2017, 16(4): 351-361.
[21] Li L, Jiang XG, Hu JY, et al. The association between interleukin-19 concentration and diabetic nephropathy[J]. BMC Nephrol, 2017, 18(1): 65.
[22] Furuichi K, Shimizu M, Hara A, et al. Diabetic nephropathy: a comparison of the clinical and pathological features between the CKD risk classification and the classification of diabetic nephropathy 2014 in Japan[J]. Intern Med, 2018, 57(23): 3345-3350.
[23] Lin CC, Chen CC, Chen FN, et al. Risks of diabetic nephropathy with variation in hemoglobin A1c and fasting plasma glucose[J]. Am J Med, 2013, 126(11): 1017.
[24] Yun KJ, Kim HJ, Kim MK, et al. Risk factors for the development and progression of diabetic kidney disease in patients with type 2 diabetes mellitus and advanced diabetic retinopathy[J]. Diabetes Metab J, 2016, 40(6): 473-481.
[25] Dorajoo SR, Ng JSL, Goh JHF, et al. HbA1c variability in type 2 diabetes is associated with the occurrence of new-onset albuminuria within three years[J]. Diabetes Res Clin Pract, 2017, 128: 32-39.
[26] Vinik AI, Park TS, Stansberry KB, et al. Diabetic neuropathies[J]. Diabetologia, 2000, 43(8): 957-973.
[27] Feldman EL, Nave KA, Jensen TS, et al. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain[J]. Neuron, 2017, 93(6): 1296-1313.
[28] Su JB, Zhao LH, Zhang XL, et al. HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients[J]. Cardiovasc Diabetol, 2018, 17(1): 47.
[29] Lai YR, Chiu WC, Huang CC, et al. HbA1c variability is strongly associated with the severity of peripheral neuropathy in patients with type 2 diabetes[J]. Front Neurosci, 2019, 13: 90.
[30] Cardoso CRL, Leite NC, Moram CBM, et al. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes[J]. Cardiovasc Diabetol, 2018, 17(1): 33.
[31] Teliti M, Cogni G, Sacchi L, et al. Risk factors for the development of micro-vascular complications of type 2 diabetes in a single-centre cohort of patients[J]. Diab Vasc Dis Res, 2018, 15(5): 424-432.
[32] Lai YR, Huang CC, Chiu WC, et al. HbA1c variability is strongly associated with the severity of cardiovascular autonomic neuropathy in patients with type 2 diabetes after longer diabetes duration[J]. Front Neurosci, 2019, 13: 458.
[33] Yang Y, Lee EY, Cho JH, et al. Cardiovascular autonomic neuropathy predicts higher HbA1c variability in subjects with type 2 diabetes mellitus[J]. Diabetes Metab J, 2018, 42(6): 496-512.
[34] Jang JY, Moon S, Cho S, et al. Visit-to-visit HbA1c and glucose variability and the risks of macrovascular and microvascular events in the general population[J]. Sci Rep, 2019, 9(1): 1374.
[35] Shen Y, Zhou J, Shi L, et al. Association between visit-to-visit HbA1c variability and the risk of cardiovascular disease in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2021, 23(1): 125-135.
[36] Sheng CS, Tian J, Miao Y, et al. Prognostic significance of long-term HbA1c variability for all-cause mortality in the ACCORD trial[J]. Diabetes Care, 2020, 43(6): 1185-1190.
Options
文章导航

/

〈 〉